Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors
核心洞察
Maze Therapeutics appointed Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors, adding deep clinical and industry experience.
The appointments come as Maze advances toward late-stage development, with additional MZE829 data in broad AMKD patients expected in late 2026 or early 2027.
Dr. Johnson brings over 30 years of cardiology and women's health expertise, while Dr. Kornowski contributes more than 35 years of biopharmaceutical leadership.
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. The announcement was made on August 13, 2026, from the company's headquarters in South San Francisco, California.
"We are excited to welcome Paula and Sophie to our Board at this important time for our company. With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year," said Jason Coloma, Ph.D., chief executive officer of Maze. "As we continue to advance Maze's pipeline toward late-stage clinical development and pre-commercial planning, both Paula and Sophie will bring a wealth of clinical and business experience to support our mission to harness the power of genetics to transform the lives of patients."
Clinical and Industry Expertise
Dr. Johnson brings over 30 years of clinical and research experience, specializing in cardiology. She has served as President of Wellesley College since 2016 and currently serves on the Board of Directors of Johnson & Johnson (J&J). Previously, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital from 2002 to 2016, and served as the Chief of the Division of Women's Health at Brigham and Women's Hospital from 2002 to 2016. She previously served as a Clinical Epidemiologist at Brigham and Women's Hospital, as a Professor of Medicine at Harvard Medical School, and as Professor of Epidemiology at the Harvard School of Public Health. She holds an M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of Public Health, and an A.B. from Harvard.
Dr. Kornowski joins Maze's Board of Directors with more than 35 years of biopharmaceutical leadership experience, most recently serving as Chief Executive Officer of Boston Pharmaceuticals beginning in 2022, focusing the company's pipeline on candidates for liver disease and leading the company to its acquisition by GlaxoSmithKline (GSK). Previously, she served as a Senior Partner at Gurnet Point Capital. Dr. Kornowski was Executive Vice-President of Roche Partnering and a member of the Extended Corporate Executive Committee of F. Hoffmann-La Roche AG and a board member of Chugai Pharmaceuticals. In that role, she led partnering and M&A strategy across early-stage compounds, late-stage assets, and technology-driven biotech companies, working closely with R&D and Commercial teams at Roche and Genentech. Earlier in her career, she held several commercial leadership roles across geographies in leading innovative pharmaceutical and diagnostic companies in France, Israel, and the U.S., notably at Roche and Merck & Co. She holds a Pharm.D. from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business.
Pipeline and Development Milestones
Maze Therapeutics harnesses the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential.
The company's pipeline is led by MZE829, a dual-mechanism APOL1 (搜索) inhibitor in Phase 2 development for APOL1-mediated kidney disease (搜索) (AMKD), and MZE782, a SLC6A19 (搜索) inhibitor in Phase 2 development with the potential to treat both phenylketonuria (搜索) (PKU) and chronic kidney disease (搜索) (CKD). The company has indicated that additional data from MZE829 in broad AMKD patients is expected in late 2026 or early 2027, with initial data from MZE782 anticipated in 2027 and additional trial initiations for both molecules planned for the following year.
Investor Engagement
In a separate announcement on September 2, 2026, Maze Therapeutics stated that company management will participate in three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference (fireside chat on Wednesday, September 9, 2026, at 9:30 a.m. ET), the Citi 2026 Biopharma Back to School Summit (fireside chat on Thursday, September 10, 2026, at 2:20 p.m. ET), and the H.C. Wainwright 28th Annual Global Investment Conference (fireside chat on Tuesday, September 15, 2026, at 9:00 a.m. ET). Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website and archived for 60 days following the presentations.